Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > New Press Release - Microbix Presents Novel HSV Test Control at EMMD

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Oct 07, 2024 10:36pm

73 Views

Post# 36257193

RE:RE:New Press Release - Microbix Presents Novel HSV Test Control at EMMD

More useful info would have been to include the size of the market in $, how novel is
MBX's product and is it price competitive.

wizzdumb wrote: This may not seem like it's not a big deal, especially if you miss these key lines:

"In spite of efforts to detect, treat, and prevent the spread of HSV, it is estimated that over half of all people worldwide are chronically infected with a strain of this virus."

"We believe our latest QAP is the first test-control that is fully consistent and reproducible for supporting both molecular and immunohistochemical analyses of HSV-infected FFPE tissue samples."